Skip to main content

Freenome, Inc.

corporate_fare Company Profile

Freenome, Inc.

FRNM·NASDAQ·Industrial Applications And Services·CIK 0002017526

Freenome is a biotechnology company that develops blood-based tests for early cancer detection. The company utilizes artificial intelligence and multiomics technology in its operations. Freenome develops and provides blood-based tests specifically for early cancer detection, including a test designed for colorectal cancer screening. Its multiomics platform integrates computational biology, machine learning, and various data types to identify biomarkers and detect different types of cancers. Freenome conducts clinical research programs, such as the PREEMPT CRC, Sanderson, and Vallania studies. These studies are aimed at validating and expanding its cancer detection tests to cover multiple cancer types. The company collaborates with healthcare organizations and partners to advance its clinical studies and enhance its product portfolio. This portfolio includes an autoantibody platform that incorporates additional biomarkers. Freenome also provides patient stratification and monitoring solutions, leveraging its multiomics technology. The company was founded in 2014 and is headquartered in Brisbane, California.

Freenome, Inc. (NASDAQ:FRNM) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 7 items for FRNM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 7 most recent items scored 7 or higher, the top rating is 9/10, with 4 rated 8 or above. Recent SEC coverage for FRNM spans 10-Q, S-1, 8-K/A.

Recent high-impact activity:

  • Freenome Posts $60.1M Q3 Profit on $183.5M Revenue; $430M Cash Funds Runway Into 2028
  • Freenome Swings to $60M Profit on $183.5M Q3 Revenue After FDA Nod
  • Freenome Launches SimpleScreen Lung, Bundles Lung and CRC Screening in One Blood Draw
  • Freenome Registers 75.1M Shares for Resale by Existing Holders, Creating Significant Stock Overhang
  • Freenome Files Amended 8-K with First Post-Merger Financials and Pro Forma Data

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
$837.47K
Op. Cash Flow
-$864.65K
Operating Income
-$2.98M
Cash & Equivalents
$865.03K
Debt / Equity
0.00×
Source: 10-K · filed 2026-03-12 · accession 0001140361-26-009262

Short Interest & Short Volume

8.08 days to cover

FINRA reported short interest of 4,633,222 shares in FRNM as of the October 30, 2026 settlement, a 3.4% increase from the prior period — about 8.1 days to cover at its recent average daily volume. On November 20, 2026, 41.7% of FRNM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,633,222 shares as of October 30, 2026
Change vs prior period▲ 3.4%
Days to cover8.08 at avg daily volume of 573,536
Daily short volume (FINRA facilities)41.7% of 258,468 shares on November 20, 2026
5-day average short volume49.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for FRNM, detected from its recent SEC filings.

1 shelf registration

Massive Share Resale Registration · Minimal Proceeds to Company

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with F →
$9.37 +0.11% today
52-week range · as of 2026-11-12 $9.37 – $17.5
Market cap
$1.04B
Volume
621.8K (0.8× avg)
3-mo avg 818.2K
Live data · 2026-11-22 07:23 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed FRNM - Latest Insights

FRNM
Nov 12, 2026, 5:29 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.61
Real-time Price: $9.37 info
Change: -$1.24 (-12%) info
Market Cap: $1.044B info
FRNM
Nov 10, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.69
Real-time Price: $9.37 info
Change: -$1.32 (-12%) info
Market Cap: $1.044B info
FRNM
Oct 20, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $12.13
Real-time Price: $9.37 info
Change: -$2.76 (-23%) info
Market Cap: $1.044B info
FRNM
Aug 18, 2026, 4:51 PM EDT
Filing Type: S-1
Importance Score:
9
Price at Filing: $13.45
Real-time Price: $9.37 info
Change: -$4.08 (-30%) info
Market Cap: $1.044B info
FRNM
Aug 13, 2026, 5:28 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $11.61
Real-time Price: $9.37 info
Change: -$2.24 (-19%) info
Market Cap: $1.044B info
FRNM
Aug 12, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $12.29
Real-time Price: $9.37 info
Change: -$2.92 (-24%) info
Market Cap: $1.044B info
FRNM
Jul 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $12.21
Real-time Price: $9.37 info
Change: -$2.84 (-23%) info
Market Cap: $1.044B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets